Abstract
The Major Histocompatibility Complex Class II locus is the primary genetic linkage to autoimmune diseases. Susceptibility to each such disease is linked to different alleles, with a few alleles showing also dominant protection. The design of vaccines for autoimmune diseases is a long sought-after goal. As knowledge about the pathogenesis of these diseases has increased, the tools for such an approach have of necessity been refined. We review below the structural essence of MHC II-linked autoimmune diseases which centers on the binding of antigenic peptides to the disease-linked MHC II proteins, and the consequent activation of cognate TCRs from pathogenic CD4+ T cells. The state of affairs in two organ-specific autoimmune diseases, type 1 diabetes, celiac disease are covered, including attempts to treat these via antigen-specific MHC II-guided measures. We offer a couple of testable suggestions as to how this approach could be improved.
Keywords: APL, autoimmunity, HLA, MHC, vaccines
Current Pharmaceutical Design
Title: Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Volume: 15 Issue: 28
Author(s): Antonis K. Moustakas and George K. Papadopoulos
Affiliation:
Keywords: APL, autoimmunity, HLA, MHC, vaccines
Abstract: The Major Histocompatibility Complex Class II locus is the primary genetic linkage to autoimmune diseases. Susceptibility to each such disease is linked to different alleles, with a few alleles showing also dominant protection. The design of vaccines for autoimmune diseases is a long sought-after goal. As knowledge about the pathogenesis of these diseases has increased, the tools for such an approach have of necessity been refined. We review below the structural essence of MHC II-linked autoimmune diseases which centers on the binding of antigenic peptides to the disease-linked MHC II proteins, and the consequent activation of cognate TCRs from pathogenic CD4+ T cells. The state of affairs in two organ-specific autoimmune diseases, type 1 diabetes, celiac disease are covered, including attempts to treat these via antigen-specific MHC II-guided measures. We offer a couple of testable suggestions as to how this approach could be improved.
Export Options
About this article
Cite this article as:
Moustakas K. Antonis and Papadopoulos K. George, Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases, Current Pharmaceutical Design 2009; 15 (28) . https://dx.doi.org/10.2174/138161209789105117
DOI https://dx.doi.org/10.2174/138161209789105117 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design A Neutralization scFv Antibody against IL-1β Isolated from a NIPA-based Bacterial Display Library
Current Pharmaceutical Biotechnology Boosting Interleukin-10 Production: Therapeutic Effects and Mechanisms
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets Editorial: (Thematic Issue: Autoimmune diseases: What have we learned from mice?)
Current Pharmaceutical Design Inhibitors Targeting the LFA-1/ICAM-1 Cell-Adhesion Interaction: Design and Mechanism of Action
Current Pharmaceutical Design CCL17/Thymus and Activation-Related Chemokine: A biomarker for Churg-Strauss Syndrome?
Current Biomarkers (Discontinued) SAGE Application in Hematological Research
Current Pharmaceutical Biotechnology An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy Immunotherapy for Multiple Sclerosis: Basic Insights for New Clinical Strategies
Current Neurovascular Research Updates on GMSCs Treatment for Autoimmune Diseases
Current Stem Cell Research & Therapy Current and Future Therapeutic Targets of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Introduction from Editor-in-Chief
Current Rheumatology Reviews Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Estrogen, A Double-Edged Sword: Modulation of TH1- and TH2-Mediated Inflammations by Differential Regulation of TH1 / TH2 Cytokine Production
Current Drug Targets - Inflammation & Allergy T Cell-Activated Signaling Pathways and Locally Produced Cytokines as Potential Targets in Celiac Disease
Current Drug Targets Multivalent Compounds for Antigen-Specific B Cell Tolerance and Treatment of Autoimmune Diseases
Current Medicinal Chemistry Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?
Current Medicinal Chemistry Synthetic Peptides Derived from Ribosomal Proteins of Leishmania spp. in Mucocutaneous Leishmaniasis: Diagnostic Usefulness
Protein & Peptide Letters